Antibodies are back for thymic attack in cGVHD
In this issue of Blood, Jin et al uncover how antibodies contribute to B-and T-cell pathology in sclerodermatous chronic graft-versus-host disease (cGVHD). 1 
G
iven that cGVHD patients are often cured of their cancer or other primary blood/ marrow disease by allogeneic hematopoietic cell transplantation (HCT), the morbidity and sometimes lethality of cGVHD is especially tragic. For many long-term HCT survivors, cGVHD remains an untreatable, relentlessly morbid condition. Effective prophylaxis and treatment of cGVHD has been significantly hampered by the lack of understanding of the pathophysiology of cGVHD.
Studies in murine models continue to improve our understanding of the immunopathologic mechanisms of cGVHD, much as they did in acute GVHD. Animal studies, including some by the authors of this current paper and others, have confirmed that disease-mediating lymphocytes arise in recipients of allogeneic donor transplants and that these cells are capable of causing autoimmune disease in syngeneic animals. Insidious development of pleiotropic autoimmune disease manifestations in murine models and in patients after allogeneic HCT, but not autologous HCT, suggest that alloreactivity incites autoreactivity. 2, 3 Separating the distinct cGVHD events that result in ongoing broad reactivity to nonpolymorphic antigens and recipient tissues from specific immunologic reactions to malignant cells will be pivotal for developing more active and specific cGVHD treatments.
Elegant experiments in murine models have substantiated specific roles for B-and T-cell subsets in cGVHD development. 4 Collectively, this manuscript and other cGVHD murine studies point out that the kinetics of immunologic events appear to be highly relevant in the pathobiology of cGVHD. Although robust germinal center (GC) formation appears to be critical for disease initiation, 5 the current study reveals that GC disruption is also important for disease maintenance. The data suggest that antibody targeting of both primary and secondary lymphoid organs results in a vicious selfdestructive cycle of these tissues in cGVHD. Perhaps ongoing primary lymphoid destruction leads to critical levels of lymphopenia such that out-competition by autoreactive B-and/or T-cell clones for factors and niches can occur. Additional experiments addressing this possibility are warranted. Taken together, it appears that the immune system over time after allogeneic HCT becomes its own worst enemy (see figure) . Organs that produce cGVHD-inciting cells are subsequently destroyed by those very cells or their cellular products, IgG. Further studies addressing this paradigm will lead us to pathways that afford targeting of pathological immune cells while preserving normal integrity of hematolymphoid organ systems.
Allogeneic HCT is the only known curative option for many patients afflicted with lifethreatening blood, bone marrow, or lymph node disorders. Immune pathology in the form of cGVHD develops in 30% to 80% of HCT patients, carrying an impact on morbidity and survival that has not improved significantly over the last 30-plus years. It appears the old adage is correct: persistence is a virtue. With National Institutes of Health consensus conference initiatives and strong collaborative efforts by the cGVHD research community, things are now moving rapidly in the right direction! Including this current paper, a surge of human and murine studies over the last several years has led to significant improvement in the understanding of the cGVHD process. As we gain more knowledge about the importance of immune recovery and immune homeostasis, along with the distinct functional capacities of key lymphoid subsets, increasing numbers of viable treatments will become available for our patients.
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